Executive Summary ..................................................5
SWOT Analysis..........................................................6
Israel Pharmaceuticals And Healthcare Industry SWOT................................................ 6
Israel Political SWOT............... 7
Israel Economics SWOT ................................................................................................. 8
Israel Business Environment SWOT ............................................................................... 8
Pharmaceutical Business Environment Ratings ..........................................................................................9
Table: Middle East and Africa – Regional Pharmaceuticals Business Environment Ratings For Q210................................................................ 9
Limits To Potential Returns .......................................................................................... 10
Risks To Realisation Of Returns ................................................................................... 10
Israel – Market Summary........................................12
Regulatory Regime..................................................13
Intellectual Property............... 13
Recent IP Developments ............................................................................................... 15
Shortcomings Of The IP Environment........................................................................... 15
Counterfeit Drugs ................... 18
Table: Top 10 Countries By Counterfeit Pharmaceutical Seizures, 2006 ...................... 18
Pricing System........................ 19
Price Cuts ............................... 20
Reimbursement System ................................................................................................. 20
Recent Reimbursement Developments........................................................................... 21
Funding For Reimbursement ........................................................................................ 22
Industry Trends and Developments .......................24
Epidemiology.......................... 24
Healthcare Sector ................... 25
Healthcare Insurance ................................................................................................... 26
Recent Healthcare Coverage Developments ................................................................. 27
Healthcare Financing................................................................................................... 28
Retail Pharmacy Sector ................................................................................................ 29
Research And Development Sector ............................................................................... 29
Table: Israel's R&D Law – Conditions For OCS Funding........................................... 31
Biotechnology ......................... 31
Recent Biotechnology Developments ............................................................................ 32
International Research And Development Co-operation .............................................. 33
Private Sector ......................... 34
Medical Device Industry............................................................................................... 34
Recent Medical Device Company Developments .......................................................... 35
Industry Forecast Scenario....................................37
Overall Market Forecast............................................................................................... 37
Key Growth Factors – Industry..................................................................................... 39
Key Growth Factors – Macroeconomic ........................................................................ 40
Table: Israel – Economic Activity................................................................................. 42
Prescription Market Forecast....................................................................................... 43
Patented Market Forecast............................................................................................. 44
Generic Drug Market Forecast..................................................................................... 45
OTC Market Forecast................................................................................................... 46
Medical Device Market Forecast.................................................................................. 47
Pharmaceutical Trade Forecast ................................................................................... 48
Other Healthcare Data Forecasts................................................................................. 50
Key Risks To Forecast Scenario......................................................................... 51
Competitive Landscape..........................................52
Pharmaceutical Industry............................................................................................... 52
Recent Pharmaceutical Industry Developments............................................................ 53
Company Profiles....................................................56
Indigenous Manufacturer Profiles ..................................................................................... 56
Teva Pharmaceutical Industries ................................................................................... 56
Taro ........................................ 61
Perrigo (Agis Industries) .............................................................................................. 64
Dexcel..................................... 67
Trima ...................................... 69
Rekah...................................... 70
Multinationals.............................. 72
Pfizer ...................................... 72
GlaxoSmithKline..................... 74
Novartis .................................. 75
Sanofi-Aventis......................... 75
Merck & Co ............................ 77
Country Snapshot: Israel Demographic Data........78
Section 1: Population.............. 78
Table: Demographic Indicators, 2005-2030................................................................. 78
Table: Rural/Urban Breakdown, 2005-2030 ................................................................ 79
Section 2: Education And Healthcare........................................................................... 79
Table: Education, 2002-2005 ....................................................................................... 79
Table: Vital Statistics, 2005-2030................................................................................. 79
Section 3: Labour Market And Spending Power ........................................................... 80
Table: Employment Indicators, 2001-2006................................................................... 80
Table: Consumer Expenditure, 2000-2012 (US$) ......................................................... 80
Table: Average Annual Wages, 2000-2012................................................................... 81
Methodology ....................................................82
How We Generate Our Pharmaceutical Industry Forecasts .............................................. 82
Pharmaceutical Business Environment Ratings Methodology ........................................... 83
Ratings Overview.................... 83
Table: Pharmaceutical Business Environment Indicators ............................................ 84
Weighting................................ 85
Table: Weighting Of Components ................................................................................. 85
Sources ........................................ 85
Forecast Tables .......................................................86